Rudnick Wallis, Cayen Joëlle, Bartoszko Jessica J, Belanger Jana, Bessey Chris, Bos Siske, Conly John, Dutrisac Ginette, Jenkins Jenna, Lee Edith, Pasay Darren, Pelude Linda, Rahier Alicia, Thirion Daniel J G
, PhD, is with the Public Health Agency of Canada, Ottawa, Ontario.
, BHSc, is with the Public Health Agency of Canada, Ottawa, Ontario.
Can J Hosp Pharm. 2024 Dec 11;77(4):e3595. doi: 10.4212/cjhp.3595. eCollection 2024.
Antimicrobial use data from inpatients in northern Canada suitable to inform stewardship programs are limited.
As a special project of the Canadian Nosocomial Infection Surveillance Program, to describe antimicrobial use for inpatients in northern Canadian acute care hospitals.
Participating acute care hospitals serving adult or mixed adult and pediatric populations in northern Canada submitted annual data on the use of all systemic antimicrobials from 2019 to 2021. Patient-day denominators were also submitted. Northern Canada was defined as the territories and Statistics Canada's provincial north. Data were analyzed in terms of defined daily doses per 1000 patient days (DDD/1000pd), as per the Anatomical Therapeutic Chemical classification system. Antimicrobials were categorized using the World Health Organization's AWaRe (Access/ Watch/Reserve) classification system.
Each year, 42-47 hospitals participated. More than 90% of participating hospitals were in Alberta or British Columbia. There was large variation in overall antimicrobial use between hospitals (e.g., interquartile range 429 to 779 DDD/1000pd in 2021). From 2019 to 2021, there was a 49% relative increase in antimicrobial use, from 401 to 596 DDD/1000pd ( = 0.11). Over the same period, the use of third- and first-generation cephalosporins increased by 80% and 64%, respectively; antimicrobials in the "Reserve" category increased from 0.4% to 2% of overall use.
This study represents the largest collection of antimicrobial use data for inpatients in northern Canada to date. From 2019 to 2021, there was an increase in antimicrobial use of 195 DDD/1000pd, largely driven by increases in the use of third- and first-generation cephalosporins. The findings should be interpreted with caution, as results may not be generalizable to all northern hospitals.
加拿大北部适合为管理计划提供信息的住院患者抗菌药物使用数据有限。
作为加拿大医院感染监测计划的一个特别项目,描述加拿大北部急症护理医院住院患者的抗菌药物使用情况。
加拿大北部为成人或成人与儿童混合人群提供服务的参与急症护理医院提交了2019年至2021年所有全身用抗菌药物使用的年度数据。还提交了以患者日为分母的数据。加拿大北部定义为各地区以及加拿大统计局划定的省级北部地区。根据解剖治疗学化学分类系统,数据以每1000患者日限定日剂量(DDD/1000pd)进行分析。抗菌药物使用世界卫生组织的AWaRe(准入/观察/储备)分类系统进行分类。
每年有42 - 47家医院参与。超过90%的参与医院位于艾伯塔省或不列颠哥伦比亚省。各医院之间总体抗菌药物使用存在很大差异(例如,2021年四分位距为429至779 DDD/1000pd)。2019年至2021年,抗菌药物使用相对增加了49%,从401 DDD/1000pd增至596 DDD/1000pd( = 0.11)。同期,第三代和第一代头孢菌素的使用分别增加了80%和64%;“储备”类抗菌药物的使用从总体使用的0.4%增至2%。
本研究是迄今为止加拿大北部住院患者抗菌药物使用数据的最大规模收集。2019年至2021年,抗菌药物使用增加了195 DDD/1000pd,主要由第三代和第一代头孢菌素使用的增加推动。由于结果可能不适用于所有北部医院,因此对这些发现的解读应谨慎。